Talk:Cyclooxygenase: Difference between revisions
→Merger proposal: new section |
m Maintain {{WPBS}}: 2 WikiProject templates. Keep majority rating "C" in {{WPBS}}. Remove 2 same ratings as {{WPBS}} in {{WikiProject Molecular Biology}}, {{WikiProject Pharmacology}}. Tag: |
||
(19 intermediate revisions by 11 users not shown) | |||
Line 1: | Line 1: | ||
{{WikiProject banner shell|collapsed=yes|class=C|1= |
|||
{{WPB| |
|||
{{ |
{{WikiProject Molecular Biology|MCB=yes|MCB-importance=mid}} |
||
{{WikiProject Pharmacology |
{{WikiProject Pharmacology|importance=high}} |
||
{{WPMED|class=C|importance=Low}} |
|||
}} |
}} |
||
{{Reliable sources for medical articles}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
==Cox-2== |
==Cox-2== |
||
Line 14: | Line 11: | ||
Added new reference from meta-analysis of side-effects, but can't get the reference format to match the existing numbering system - can someone figure this out? [[User:Apers0n|apers0n]] 18:39, 9 June 2006 (UTC) |
Added new reference from meta-analysis of side-effects, but can't get the reference format to match the existing numbering system - can someone figure this out? [[User:Apers0n|apers0n]] 18:39, 9 June 2006 (UTC) |
||
:Fixed the numbering problem. The '#' numbered-item system gives a count to items. The ref template has its own numbering count. If (and only if) every '#' item is referenced by a ref template in the article, then the numbering stays synchornous. If we have references that aren't explicitly linked in the article, they need to be at the end of the References list. I prefer the Harvard referencing myself. [[User:David.Throop|David.Throop]] 17:36, 12 June 2006 (UTC) |
:Fixed the numbering problem. The '#' numbered-item system gives a count to items. The ref template has its own numbering count. If (and only if) every '#' item is referenced by a ref template in the article, then the numbering stays synchornous. If we have references that aren't explicitly linked in the article, they need to be at the end of the References list. I prefer the Harvard referencing myself. [[User:David.Throop|David.Throop]] 17:36, 12 June 2006 (UTC) |
||
I find the cox-2 paragraph misleading...the sentence structure could use some work. <small>—Preceding [[Wikipedia:Signatures|unsigned]] comment added by [[User:Herma063|Herma063]] ([[User talk:Herma063|talk]] • [[Special:Contributions/Herma063|contribs]]) 14:55, 20 January 2008 (UTC)</small><!-- Template:Unsigned --> <!--Autosigned by SineBot--> |
I find the cox-2 paragraph misleading...the sentence structure could use some work. <small>—Preceding [[Wikipedia:Signatures|unsigned]] comment added by [[User:Herma063|Herma063]] ([[User talk:Herma063|talk]] • [[Special:Contributions/Herma063|contribs]]) 14:55, 20 January 2008 (UTC)</small><!-- Template:Unsigned --> <!--Autosigned by SineBot--> |
||
The chemical structure of arachidonic acid is wrong. It should have 4 cis bonds instead of 4 trans bonds. This is pretty significant in the activity of the enzyme and the resultant formation of prostanoids.[[Special:Contributions/98.209.0.223|98.209.0.223]] ([[User talk:98.209.0.223|talk]]) 20:32, 17 January 2009 (UTC)David Fichtner (Chemist in Ann Arbor, MI) |
The chemical structure of arachidonic acid is wrong. It should have 4 cis bonds instead of 4 trans bonds. This is pretty significant in the activity of the enzyme and the resultant formation of prostanoids.[[Special:Contributions/98.209.0.223|98.209.0.223]] ([[User talk:98.209.0.223|talk]]) 20:32, 17 January 2009 (UTC)David Fichtner (Chemist in Ann Arbor, MI) |
||
The 13,14 double bond is missing on the last two structures of the scheme. Showing all half arrows in the mechanism will also help the reader to follow ring closures, etc. <small><span class="autosigned">— Preceding [[Wikipedia:Signatures|unsigned]] comment added by [[User:Marchchem|Marchchem]] ([[User talk:Marchchem|talk]] • [[Special:Contributions/Marchchem|contribs]]) 01:02, 4 June 2011 (UTC)</span></small><!-- Template:Unsigned --> <!--Autosigned by SineBot--> |
|||
==Non-NSAID??== |
==Non-NSAID??== |
||
Line 35: | Line 32: | ||
== Merger proposal == |
== Merger proposal == |
||
* '''oppose'''– If |
* '''oppose''' – If the [[PTGS1]] article is merged into into this article, then [[PTGS2]] should also be merged. However it is not practical to merge two large {{tl|GNF_Protein_box}} templates (''i.e.'', {{tl|PBB/5742}} and {{tl|PBB/5743}}) into the same article. [[User:Boghog2|Boghog]] ([[User talk:Boghog2|talk]]) 20:01, 2 March 2010 (UTC) |
||
* '''oppose''' - Merge suggestion tag should be removed. I agree with above. There are many cases of similar proteins. Would you merge all GPCRs under one page, for example? [[User:Johnfravolda|Johnfravolda]] ([[User talk:Johnfravolda|talk]]) 16:28, 6 April 2010 (UTC) |
|||
== Acetaminophen == |
|||
I am moving the complete acetaminophen part to this place. I am not aware that there was ever a consensus to classify acetaminophen as non-NSAID and recent work such as {{PMID|17884974}} show that it is in fact an NSAID. COX-3 is problematical as well, so I see no point in trying to save anything in this part - original text bellow. [[User:Richiez|Richiez]] ([[User talk:Richiez|talk]]) 23:16, 28 March 2010 (UTC) |
|||
It has been suggested that [[acetaminophen]], also known as [[paracetamol]], reversibly inhibits ''COX-3'', although there is now considerable doubt about this theory. Since it has no effect on inflammation, it is not classed as an NSAID.<ref name="pmid12374850">{{cite journal | author = Warner TD, Mitchell JA | title = Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 99 | issue = 21 | pages = 13371–3 | year = 2002 | month = October | pmid = 12374850 | pmc = 129677 | doi = 10.1073/pnas.222543099 | url = }}</ref><ref name="pmid12697726">{{cite journal | author = Soberman RJ, Christmas P | title = The organization and consequences of eicosanoid signaling | journal = J. Clin. Invest. | volume = 111 | issue = 8 | pages = 1107–13 | year = 2003 | month = April | pmid = 12697726 | pmc = 152944 | doi = 10.1172/JCI18338 | url = }}</ref> |
|||
{{reflist-talk}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
:I have signed this "high" importance in both Pharmacology and Medicine.[[User:JustAnotherKinase|JustAnotherKinase]] ([[User talk:JustAnotherKinase|talk]]) 14:47, 1 May 2011 (UTC) |
|||
:: Agreed that this article is high importance to Pharmacology. One could debate however whether this is high importance to Medicine, not because it unimportant, rather because Medicine is such a broad field and a particular enzyme, regardless of its clinical importance, is somewhat peripheral to the field of Medicine. [[User:Boghog|Boghog]] ([[User talk:Boghog|talk]]) 15:11, 1 May 2011 (UTC) |
|||
::: According to the [[Wikipedia:WikiProject_Medicine/Assessment#Importance_scale|medicine article importance scale]], a "mid" rated article ''is notable within its particular specialty''. I think this article clearly falls within that category, so I have changed the Medicine importance rating from high to mid. [[User:Boghog|Boghog]] ([[User talk:Boghog|talk]]) 15:17, 1 May 2011 (UTC) |
Latest revision as of 08:43, 13 February 2024
This article is rated C-class on Wikipedia's content assessment scale. It is of interest to multiple WikiProjects. | ||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Cyclooxygenase.
|
Cox-2
[edit]"Cox-2-selectivity does not seem to affect other side-effects of NSAIDs (most notably an increased risk of renal failure), and some non-significant results have aroused the suspicion that there might be an increase in the risk for myocardial infarction and thrombosis by a relative increase in thromboxane." Rofecoxib has been shown (as of today, September 30 2004) to actually increase the risk of myocardial infarction, and has been pulled off the shelf by order of the FDA - pretty significant eh? :) Maybe when more is known about COX-2 inhibitors we can add a blurb here. -- Orestes
Reference numbering
[edit]Added new reference from meta-analysis of side-effects, but can't get the reference format to match the existing numbering system - can someone figure this out? apers0n 18:39, 9 June 2006 (UTC)
- Fixed the numbering problem. The '#' numbered-item system gives a count to items. The ref template has its own numbering count. If (and only if) every '#' item is referenced by a ref template in the article, then the numbering stays synchornous. If we have references that aren't explicitly linked in the article, they need to be at the end of the References list. I prefer the Harvard referencing myself. David.Throop 17:36, 12 June 2006 (UTC)
I find the cox-2 paragraph misleading...the sentence structure could use some work. —Preceding unsigned comment added by Herma063 (talk • contribs) 14:55, 20 January 2008 (UTC)
The chemical structure of arachidonic acid is wrong. It should have 4 cis bonds instead of 4 trans bonds. This is pretty significant in the activity of the enzyme and the resultant formation of prostanoids.98.209.0.223 (talk) 20:32, 17 January 2009 (UTC)David Fichtner (Chemist in Ann Arbor, MI)
The 13,14 double bond is missing on the last two structures of the scheme. Showing all half arrows in the mechanism will also help the reader to follow ring closures, etc. — Preceding unsigned comment added by Marchchem (talk • contribs) 01:02, 4 June 2011 (UTC)
Non-NSAID??
[edit]"NON-Non-steroidal anti-inflammatory drugs" must mean that it is a "steroidal anti-inflammatory drug" which paracetamol (which is listed in this section) clearly is not. Some other headline perhaps? maybe "Other NSAID´s" or "NSAID´s with other mechanisms" Christian Nissen —Preceding unsigned comment added by 87.227.59.31 (talk) 09:26, 16 April 2008 (UTC)
- Nope. This section talks about acetiminophen, which has no effect on inflammation; it is neither an NSAID nor a steroidal anti-inflammatory. It is merely an analgesic with no effect on inflammation. 69.248.158.72 (talk) 05:35, 28 December 2008 (UTC)
Is COX-2 hardly found in normal tissues?
[edit]I saw an article in NCBI that said it was an old concept. The author of the article said they proved that COX-2 found in the normal tissue is more than we expect.Hehehahaeveryday (talk) 07:18, 21 September 2008 (UTC)
The paradigm of constitutive COX1 expression and inducible COX2 expression is an over-simplfication. COX-2 is constitutively expressed in several tissues (inlcuding the kidney), although it is better known for its roles in inflammation, and is induced at high levels in immune cells by proinflammatory stimuli. COX1 is constitutively expressed in many different cells, however expression can be induced or increased under certain circumstances, much like COX2. JustAnotherKinase (talk) 21:50, 5 October 2009 (UTC)
Merger proposal
[edit]- oppose – If the PTGS1 article is merged into into this article, then PTGS2 should also be merged. However it is not practical to merge two large {{GNF_Protein_box}} templates (i.e., {{PBB/5742}} and {{PBB/5743}}) into the same article. Boghog (talk) 20:01, 2 March 2010 (UTC)
- oppose - Merge suggestion tag should be removed. I agree with above. There are many cases of similar proteins. Would you merge all GPCRs under one page, for example? Johnfravolda (talk) 16:28, 6 April 2010 (UTC)
Acetaminophen
[edit]I am moving the complete acetaminophen part to this place. I am not aware that there was ever a consensus to classify acetaminophen as non-NSAID and recent work such as PMID 17884974 show that it is in fact an NSAID. COX-3 is problematical as well, so I see no point in trying to save anything in this part - original text bellow. Richiez (talk) 23:16, 28 March 2010 (UTC)
It has been suggested that acetaminophen, also known as paracetamol, reversibly inhibits COX-3, although there is now considerable doubt about this theory. Since it has no effect on inflammation, it is not classed as an NSAID.[1][2]
References
- ^ Warner TD, Mitchell JA (2002). "Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?". Proc. Natl. Acad. Sci. U.S.A. 99 (21): 13371–3. doi:10.1073/pnas.222543099. PMC 129677. PMID 12374850.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Soberman RJ, Christmas P (2003). "The organization and consequences of eicosanoid signaling". J. Clin. Invest. 111 (8): 1107–13. doi:10.1172/JCI18338. PMC 152944. PMID 12697726.
{{cite journal}}
: Unknown parameter|month=
ignored (help)
Importance
[edit]How can this article be rated as low importance for medicine (and not rated for pharmacology?) Aspirin is one of the most widely used drugs in the history of medicine! John Vane shared the Nobel Prize in medicine in 1982 for the work that let to the discovery that aspirin works by inhibiting COX1. JustAnotherKinase (talk) 21:50, 5 October 2009 (UTC)
- I have signed this "high" importance in both Pharmacology and Medicine.JustAnotherKinase (talk) 14:47, 1 May 2011 (UTC)
- Agreed that this article is high importance to Pharmacology. One could debate however whether this is high importance to Medicine, not because it unimportant, rather because Medicine is such a broad field and a particular enzyme, regardless of its clinical importance, is somewhat peripheral to the field of Medicine. Boghog (talk) 15:11, 1 May 2011 (UTC)
- According to the medicine article importance scale, a "mid" rated article is notable within its particular specialty. I think this article clearly falls within that category, so I have changed the Medicine importance rating from high to mid. Boghog (talk) 15:17, 1 May 2011 (UTC)
- C-Class Molecular Biology articles
- Unknown-importance Molecular Biology articles
- C-Class MCB articles
- Mid-importance MCB articles
- WikiProject Molecular and Cellular Biology articles
- All WikiProject Molecular Biology pages
- C-Class pharmacology articles
- High-importance pharmacology articles
- WikiProject Pharmacology articles